Biosensing · AI · Longevity

Intelligence
from within

Oravé Labs develops AI-driven biosensing technologies that transform biological signals into real-time health intelligence — non-invasive, continuous, and built for daily life.

Preventive HealthAI Biomarker IntelligenceNon-Invasive SensingMonaco · Nice · BucharestEarly Access — Late 2026Preventive HealthAI Biomarker IntelligenceNon-Invasive SensingMonaco · Nice · BucharestEarly Access — Late 2026

Redefining what it means
to know your body

The majority of preventable chronic conditions are preceded by measurable biological changes that go undetected for years. Current diagnostics are episodic, invasive, and reactive — designed to identify disease, not prevent it.

Oravé Labs is building the infrastructure for a different paradigm: continuous, non-invasive biosensing combined with AI-driven longitudinal analysis, designed to surface meaningful health signals before they become clinical events.

80%
of chronic diseases are preventable with early intervention
7y
average delay between first biomarker signal and clinical diagnosis
$6T
projected global cost of chronic disease by 2030
Biological signal · AI interpretation · Health intelligence
RAW SIGNALAI PROCESSEDINSIGHT
Continuous monitoringReal-time analysisLongitudinal patternsPredictive intelligenceNon-invasive

Advanced
biosensing,
reimagined

We are building next-generation sensing technologies designed to capture meaningful biological signals through seamless, everyday interactions — powered by machine learning that improves with every data point.

01
Biomarker Intelligence

Advanced biosensing approaches designed to capture meaningful biological signals — continuously, non-invasively, and without disrupting daily routine.

02
AI-Driven Insights

Complex biological signals transformed into clear health intelligence through machine learning models built on longitudinal personal data.

03
Seamless Integration

Health technology designed to fit naturally into existing daily behaviours — not another device to manage, but an invisible layer of biological awareness.

Phase 01
Stealth R&D
2024 – 2025
Core biosensing technology development. Signal processing architecture. AI model foundation.
Phase 02
Early Access
Late 2026
Closed cohort of selected participants. Platform validation. Iterative refinement with real-world data.
Phase 03
Beta Launch
2027
Expanded access. Clinical partnerships. Longitudinal study initiation. Integration ecosystem.
Phase 04
Full Launch
2028
Consumer and B2B market entry. Regulatory pathway completion. International expansion.
Dr. Alexandru Boamfă
Dr. Alexandru Boamfă
Founder & CEO
20 years as an oral surgeon with deep clinical expertise in biological diagnostics and human physiology. Leading Oravé Labs's vision, strategy and long-term direction.
LinkedIn ↗
Dr. Elena Magdalena Duculescu
Dr. Elena Magdalena Duculescu
Chief Medical Officer · Head of Clinical Research
20 years as a cardiologist with deep expertise in cardiovascular diagnostics and clinical research. Leading Oravé's medical direction and clinical validation programme.
LinkedIn ↗
Dr. Cristina Iancu
Dr. Cristina Iancu
Co-Founder · Clinical Affairs
10 years in general dentistry with extensive clinical experience in oral biology and patient diagnostics. Overseeing clinical affairs and operational validation of Oravé's platform.
LinkedIn ↗
Bogdan Boamfă
Bogdan Boamfă
Co-Founder · Platform Architect & IT Lead
Fractional CTO with extensive experience in platform architecture and engineering leadership. Directing all technology infrastructure at Oravé Labs.
LinkedIn ↗
Cristian Gamentz
Cristian Gamentz
Co-Founder · Business Development & Executive Management
20 years in business development, executive management and marketing. Driving Oravé's commercial strategy and strategic partnerships.
LinkedIn ↗
Engineering partners

Questions
answered

Yes. Oravé's biosensing approach is designed entirely around non-invasive signal capture — no needles, no blood draws, no disruption to your daily routine. Our methods are based on detecting biological signals through natural daily interactions.
The platform is designed to surface longitudinal biomarker trends and patterns rather than isolated readings — a continuous baseline of your biological state, with AI-generated insights that flag meaningful changes over time.
We are looking for health-conscious individuals, clinicians or researchers interested in the science, and institutional partners. Each group plays a different role in validating and shaping the platform before broader launch.
We are targeting a closed Early Access cohort for late 2026, with a broader beta in 2027. Signing up to the waitlist ensures you are considered for the first cohort.
Data privacy is foundational to our design. All biological data is encrypted, never sold, and you retain full ownership. Detailed privacy architecture will be published ahead of Early Access.
Early Access Program

Be first to
experience
the future

We are selecting a small group of early participants to shape the development of our platform. Share your interest and we will be in touch ahead of our 2026 launch.

No spam. We will only reach out when it matters.

How we handle
your data

Last updated: January 2025

Who we are

Oravé Labs is a health technology company incorporated in Monaco, with operations in Nice (France) and Bucharest (Romania). We are building an AI-driven biosensing platform for preventive health intelligence. This policy explains what personal data we collect, why we collect it, and how we handle it.

What data we collect

When you submit the Early Access waitlist form, we collect your name, email address, organisation (if provided), and your stated area of interest. We do not collect any biological, health, or medical data at this stage. We do not use cookies beyond those strictly necessary for the website to function.

Why we collect it

We collect your contact information solely to communicate with you about Oravé Labs — including updates on the platform, Early Access cohort selection, and relevant research developments. We will never send unsolicited commercial messages or share your data with third parties for marketing purposes.

How we store and protect it

Your form submissions are stored securely via Tally (tally.so), a GDPR-compliant form platform. Data is encrypted at rest and in transit. Access is restricted to Oravé Labs founders only. We retain your data only as long as necessary to fulfil the purpose for which it was collected.

Your rights (GDPR)

If you are located in the European Economic Area, you have the right to access, correct, or delete your personal data at any time. You may also withdraw consent, request data portability, or object to processing. To exercise any of these rights, contact us at contact@oravelabs.com and we will respond within 30 days.

Third-party services

Our website is hosted on Framer. Our form is powered by Tally. Neither service sells your data. Both are GDPR-compliant. We do not use Google Analytics, Facebook Pixel, or any other tracking technology at this stage.

Contact

For any questions regarding this privacy policy or your personal data, please contact us at: contact@oravelabs.com — Oravé Labs, Monaco.

Biosensing · AI · Longevity

Intelligence
from within

Oravé Labs develops AI-driven biosensing technologies that transform biological signals into real-time health intelligence — non-invasive, continuous, and built for daily life.

Preventive HealthAI Biomarker IntelligenceNon-Invasive SensingMonaco · Nice · BucharestEarly Access — Late 2026Preventive HealthAI Biomarker IntelligenceNon-Invasive SensingMonaco · Nice · BucharestEarly Access — Late 2026

Redefining what it means
to know your body

The majority of preventable chronic conditions are preceded by measurable biological changes that go undetected for years. Current diagnostics are episodic, invasive, and reactive — designed to identify disease, not prevent it.

Oravé Labs is building the infrastructure for a different paradigm: continuous, non-invasive biosensing combined with AI-driven longitudinal analysis, designed to surface meaningful health signals before they become clinical events.

80%
of chronic diseases are preventable with early intervention
7y
average delay between first biomarker signal and clinical diagnosis
$6T
projected global cost of chronic disease by 2030
Biological signal · AI interpretation · Health intelligence
RAW SIGNALAI PROCESSEDINSIGHT
Continuous monitoringReal-time analysisLongitudinal patternsPredictive intelligenceNon-invasive

Advanced
biosensing,
reimagined

We are building next-generation sensing technologies designed to capture meaningful biological signals through seamless, everyday interactions — powered by machine learning that improves with every data point.

01
Biomarker Intelligence

Advanced biosensing approaches designed to capture meaningful biological signals — continuously, non-invasively, and without disrupting daily routine.

02
AI-Driven Insights

Complex biological signals transformed into clear health intelligence through machine learning models built on longitudinal personal data.

03
Seamless Integration

Health technology designed to fit naturally into existing daily behaviours — not another device to manage, but an invisible layer of biological awareness.

Phase 01
Stealth R&D
2024 – 2025
Core biosensing technology development. Signal processing architecture. AI model foundation.
Phase 02
Early Access
Late 2026
Closed cohort of selected participants. Platform validation. Iterative refinement with real-world data.
Phase 03
Beta Launch
2027
Expanded access. Clinical partnerships. Longitudinal study initiation. Integration ecosystem.
Phase 04
Full Launch
2028
Consumer and B2B market entry. Regulatory pathway completion. International expansion.
Dr. Alexandru Boamfă
Dr. Alexandru Boamfă
Founder & CEO
20 years as an oral surgeon with deep clinical expertise in biological diagnostics and human physiology. Leading Oravé Labs's vision, strategy and long-term direction.
LinkedIn ↗
Dr. Elena Magdalena Duculescu
Dr. Elena Magdalena Duculescu
Chief Medical Officer · Head of Clinical Research
20 years as a cardiologist with deep expertise in cardiovascular diagnostics and clinical research. Leading Oravé's medical direction and clinical validation programme.
LinkedIn ↗
Dr. Cristina Iancu
Dr. Cristina Iancu
Co-Founder · Clinical Affairs
10 years in general dentistry with extensive clinical experience in oral biology and patient diagnostics. Overseeing clinical affairs and operational validation of Oravé's platform.
LinkedIn ↗
Bogdan Boamfă
Bogdan Boamfă
Co-Founder · Platform Architect & IT Lead
Fractional CTO with extensive experience in platform architecture and engineering leadership. Directing all technology infrastructure at Oravé Labs.
LinkedIn ↗
Cristian Gamentz
Cristian Gamentz
Co-Founder · Business Development & Executive Management
20 years in business development, executive management and marketing. Driving Oravé's commercial strategy and strategic partnerships.
LinkedIn ↗
Engineering partners

Questions
answered

Yes. Oravé's biosensing approach is designed entirely around non-invasive signal capture — no needles, no blood draws, no disruption to your daily routine. Our methods are based on detecting biological signals through natural daily interactions.
The platform is designed to surface longitudinal biomarker trends and patterns rather than isolated readings — a continuous baseline of your biological state, with AI-generated insights that flag meaningful changes over time.
We are looking for health-conscious individuals, clinicians or researchers interested in the science, and institutional partners. Each group plays a different role in validating and shaping the platform before broader launch.
We are targeting a closed Early Access cohort for late 2026, with a broader beta in 2027. Signing up to the waitlist ensures you are considered for the first cohort.
Data privacy is foundational to our design. All biological data is encrypted, never sold, and you retain full ownership. Detailed privacy architecture will be published ahead of Early Access.
Early Access Program

Be first to
experience
the future

We are selecting a small group of early participants to shape the development of our platform. Share your interest and we will be in touch ahead of our 2026 launch.

No spam. We will only reach out when it matters.

How we handle
your data

Last updated: January 2025

Who we are

Oravé Labs is a health technology company incorporated in Monaco, with operations in Nice (France) and Bucharest (Romania). We are building an AI-driven biosensing platform for preventive health intelligence. This policy explains what personal data we collect, why we collect it, and how we handle it.

What data we collect

When you submit the Early Access waitlist form, we collect your name, email address, organisation (if provided), and your stated area of interest. We do not collect any biological, health, or medical data at this stage. We do not use cookies beyond those strictly necessary for the website to function.

Why we collect it

We collect your contact information solely to communicate with you about Oravé Labs — including updates on the platform, Early Access cohort selection, and relevant research developments. We will never send unsolicited commercial messages or share your data with third parties for marketing purposes.

How we store and protect it

Your form submissions are stored securely via Tally (tally.so), a GDPR-compliant form platform. Data is encrypted at rest and in transit. Access is restricted to Oravé Labs founders only. We retain your data only as long as necessary to fulfil the purpose for which it was collected.

Your rights (GDPR)

If you are located in the European Economic Area, you have the right to access, correct, or delete your personal data at any time. You may also withdraw consent, request data portability, or object to processing. To exercise any of these rights, contact us at contact@oravelabs.com and we will respond within 30 days.

Third-party services

Our website is hosted on Framer. Our form is powered by Tally. Neither service sells your data. Both are GDPR-compliant. We do not use Google Analytics, Facebook Pixel, or any other tracking technology at this stage.

Contact

For any questions regarding this privacy policy or your personal data, please contact us at: contact@oravelabs.com — Oravé Labs, Monaco.

Biosensing · AI · Longevity

Intelligence
from within

Oravé Labs develops AI-driven biosensing technologies that transform biological signals into real-time health intelligence — non-invasive, continuous, and built for daily life.

Preventive HealthAI Biomarker IntelligenceNon-Invasive SensingMonaco · Nice · BucharestEarly Access — Late 2026Preventive HealthAI Biomarker IntelligenceNon-Invasive SensingMonaco · Nice · BucharestEarly Access — Late 2026

Redefining what it means
to know your body

The majority of preventable chronic conditions are preceded by measurable biological changes that go undetected for years. Current diagnostics are episodic, invasive, and reactive — designed to identify disease, not prevent it.

Oravé Labs is building the infrastructure for a different paradigm: continuous, non-invasive biosensing combined with AI-driven longitudinal analysis, designed to surface meaningful health signals before they become clinical events.

80%
of chronic diseases are preventable with early intervention
7y
average delay between first biomarker signal and clinical diagnosis
$6T
projected global cost of chronic disease by 2030
Biological signal · AI interpretation · Health intelligence
RAW SIGNALAI PROCESSEDINSIGHT
Continuous monitoringReal-time analysisLongitudinal patternsPredictive intelligenceNon-invasive

Advanced
biosensing,
reimagined

We are building next-generation sensing technologies designed to capture meaningful biological signals through seamless, everyday interactions — powered by machine learning that improves with every data point.

01
Biomarker Intelligence

Advanced biosensing approaches designed to capture meaningful biological signals — continuously, non-invasively, and without disrupting daily routine.

02
AI-Driven Insights

Complex biological signals transformed into clear health intelligence through machine learning models built on longitudinal personal data.

03
Seamless Integration

Health technology designed to fit naturally into existing daily behaviours — not another device to manage, but an invisible layer of biological awareness.

Phase 01
Stealth R&D
2024 – 2025
Core biosensing technology development. Signal processing architecture. AI model foundation.
Phase 02
Early Access
Late 2026
Closed cohort of selected participants. Platform validation. Iterative refinement with real-world data.
Phase 03
Beta Launch
2027
Expanded access. Clinical partnerships. Longitudinal study initiation. Integration ecosystem.
Phase 04
Full Launch
2028
Consumer and B2B market entry. Regulatory pathway completion. International expansion.
Dr. Alexandru Boamfă
Dr. Alexandru Boamfă
Founder & CEO
20 years as an oral surgeon with deep clinical expertise in biological diagnostics and human physiology. Leading Oravé Labs's vision, strategy and long-term direction.
LinkedIn ↗
Dr. Elena Magdalena Duculescu
Dr. Elena Magdalena Duculescu
Chief Medical Officer · Head of Clinical Research
20 years as a cardiologist with deep expertise in cardiovascular diagnostics and clinical research. Leading Oravé's medical direction and clinical validation programme.
LinkedIn ↗
Dr. Cristina Iancu
Dr. Cristina Iancu
Co-Founder · Clinical Affairs
10 years in general dentistry with extensive clinical experience in oral biology and patient diagnostics. Overseeing clinical affairs and operational validation of Oravé's platform.
LinkedIn ↗
Bogdan Boamfă
Bogdan Boamfă
Co-Founder · Platform Architect & IT Lead
Fractional CTO with extensive experience in platform architecture and engineering leadership. Directing all technology infrastructure at Oravé Labs.
LinkedIn ↗
Cristian Gamentz
Cristian Gamentz
Co-Founder · Business Development & Executive Management
20 years in business development, executive management and marketing. Driving Oravé's commercial strategy and strategic partnerships.
LinkedIn ↗
Engineering partners

Questions
answered

Yes. Oravé's biosensing approach is designed entirely around non-invasive signal capture — no needles, no blood draws, no disruption to your daily routine. Our methods are based on detecting biological signals through natural daily interactions.
The platform is designed to surface longitudinal biomarker trends and patterns rather than isolated readings — a continuous baseline of your biological state, with AI-generated insights that flag meaningful changes over time.
We are looking for health-conscious individuals, clinicians or researchers interested in the science, and institutional partners. Each group plays a different role in validating and shaping the platform before broader launch.
We are targeting a closed Early Access cohort for late 2026, with a broader beta in 2027. Signing up to the waitlist ensures you are considered for the first cohort.
Data privacy is foundational to our design. All biological data is encrypted, never sold, and you retain full ownership. Detailed privacy architecture will be published ahead of Early Access.
Early Access Program

Be first to
experience
the future

We are selecting a small group of early participants to shape the development of our platform. Share your interest and we will be in touch ahead of our 2026 launch.

No spam. We will only reach out when it matters.

How we handle
your data

Last updated: January 2025

Who we are

Oravé Labs is a health technology company incorporated in Monaco, with operations in Nice (France) and Bucharest (Romania). We are building an AI-driven biosensing platform for preventive health intelligence. This policy explains what personal data we collect, why we collect it, and how we handle it.

What data we collect

When you submit the Early Access waitlist form, we collect your name, email address, organisation (if provided), and your stated area of interest. We do not collect any biological, health, or medical data at this stage. We do not use cookies beyond those strictly necessary for the website to function.

Why we collect it

We collect your contact information solely to communicate with you about Oravé Labs — including updates on the platform, Early Access cohort selection, and relevant research developments. We will never send unsolicited commercial messages or share your data with third parties for marketing purposes.

How we store and protect it

Your form submissions are stored securely via Tally (tally.so), a GDPR-compliant form platform. Data is encrypted at rest and in transit. Access is restricted to Oravé Labs founders only. We retain your data only as long as necessary to fulfil the purpose for which it was collected.

Your rights (GDPR)

If you are located in the European Economic Area, you have the right to access, correct, or delete your personal data at any time. You may also withdraw consent, request data portability, or object to processing. To exercise any of these rights, contact us at contact@oravelabs.com and we will respond within 30 days.

Third-party services

Our website is hosted on Framer. Our form is powered by Tally. Neither service sells your data. Both are GDPR-compliant. We do not use Google Analytics, Facebook Pixel, or any other tracking technology at this stage.

Contact

For any questions regarding this privacy policy or your personal data, please contact us at: contact@oravelabs.com — Oravé Labs, Monaco.

Biosensing · AI · Longevity

Intelligence
from within

Oravé Labs develops AI-driven biosensing technologies that transform biological signals into real-time health intelligence — non-invasive, continuous, and built for daily life.

Preventive HealthAI Biomarker IntelligenceNon-Invasive SensingMonaco · Nice · BucharestEarly Access — Late 2026Preventive HealthAI Biomarker IntelligenceNon-Invasive SensingMonaco · Nice · BucharestEarly Access — Late 2026

Redefining what it means
to know your body

The majority of preventable chronic conditions are preceded by measurable biological changes that go undetected for years. Current diagnostics are episodic, invasive, and reactive — designed to identify disease, not prevent it.

Oravé Labs is building the infrastructure for a different paradigm: continuous, non-invasive biosensing combined with AI-driven longitudinal analysis, designed to surface meaningful health signals before they become clinical events.

80%
of chronic diseases are preventable with early intervention
7y
average delay between first biomarker signal and clinical diagnosis
$6T
projected global cost of chronic disease by 2030
Biological signal · AI interpretation · Health intelligence
RAW SIGNALAI PROCESSEDINSIGHT
Continuous monitoringReal-time analysisLongitudinal patternsPredictive intelligenceNon-invasive

Advanced
biosensing,
reimagined

We are building next-generation sensing technologies designed to capture meaningful biological signals through seamless, everyday interactions — powered by machine learning that improves with every data point.

01
Biomarker Intelligence

Advanced biosensing approaches designed to capture meaningful biological signals — continuously, non-invasively, and without disrupting daily routine.

02
AI-Driven Insights

Complex biological signals transformed into clear health intelligence through machine learning models built on longitudinal personal data.

03
Seamless Integration

Health technology designed to fit naturally into existing daily behaviours — not another device to manage, but an invisible layer of biological awareness.

Phase 01
Stealth R&D
2024 – 2025
Core biosensing technology development. Signal processing architecture. AI model foundation.
Phase 02
Early Access
Late 2026
Closed cohort of selected participants. Platform validation. Iterative refinement with real-world data.
Phase 03
Beta Launch
2027
Expanded access. Clinical partnerships. Longitudinal study initiation. Integration ecosystem.
Phase 04
Full Launch
2028
Consumer and B2B market entry. Regulatory pathway completion. International expansion.
Dr. Alexandru Boamfă
Dr. Alexandru Boamfă
Founder & CEO
20 years as an oral surgeon with deep clinical expertise in biological diagnostics and human physiology. Leading Oravé Labs's vision, strategy and long-term direction.
LinkedIn ↗
Dr. Elena Magdalena Duculescu
Dr. Elena Magdalena Duculescu
Chief Medical Officer · Head of Clinical Research
20 years as a cardiologist with deep expertise in cardiovascular diagnostics and clinical research. Leading Oravé's medical direction and clinical validation programme.
LinkedIn ↗
Dr. Cristina Iancu
Dr. Cristina Iancu
Co-Founder · Clinical Affairs
10 years in general dentistry with extensive clinical experience in oral biology and patient diagnostics. Overseeing clinical affairs and operational validation of Oravé's platform.
LinkedIn ↗
Bogdan Boamfă
Bogdan Boamfă
Co-Founder · Platform Architect & IT Lead
Fractional CTO with extensive experience in platform architecture and engineering leadership. Directing all technology infrastructure at Oravé Labs.
LinkedIn ↗
Cristian Gamentz
Cristian Gamentz
Co-Founder · Business Development & Executive Management
20 years in business development, executive management and marketing. Driving Oravé's commercial strategy and strategic partnerships.
LinkedIn ↗
Engineering partners

Questions
answered

Yes. Oravé's biosensing approach is designed entirely around non-invasive signal capture — no needles, no blood draws, no disruption to your daily routine. Our methods are based on detecting biological signals through natural daily interactions.
The platform is designed to surface longitudinal biomarker trends and patterns rather than isolated readings — a continuous baseline of your biological state, with AI-generated insights that flag meaningful changes over time.
We are looking for health-conscious individuals, clinicians or researchers interested in the science, and institutional partners. Each group plays a different role in validating and shaping the platform before broader launch.
We are targeting a closed Early Access cohort for late 2026, with a broader beta in 2027. Signing up to the waitlist ensures you are considered for the first cohort.
Data privacy is foundational to our design. All biological data is encrypted, never sold, and you retain full ownership. Detailed privacy architecture will be published ahead of Early Access.
Early Access Program

Be first to
experience
the future

We are selecting a small group of early participants to shape the development of our platform. Share your interest and we will be in touch ahead of our 2026 launch.

No spam. We will only reach out when it matters.

How we handle
your data

Last updated: January 2025

Who we are

Oravé Labs is a health technology company incorporated in Monaco, with operations in Nice (France) and Bucharest (Romania). We are building an AI-driven biosensing platform for preventive health intelligence. This policy explains what personal data we collect, why we collect it, and how we handle it.

What data we collect

When you submit the Early Access waitlist form, we collect your name, email address, organisation (if provided), and your stated area of interest. We do not collect any biological, health, or medical data at this stage. We do not use cookies beyond those strictly necessary for the website to function.

Why we collect it

We collect your contact information solely to communicate with you about Oravé Labs — including updates on the platform, Early Access cohort selection, and relevant research developments. We will never send unsolicited commercial messages or share your data with third parties for marketing purposes.

How we store and protect it

Your form submissions are stored securely via Tally (tally.so), a GDPR-compliant form platform. Data is encrypted at rest and in transit. Access is restricted to Oravé Labs founders only. We retain your data only as long as necessary to fulfil the purpose for which it was collected.

Your rights (GDPR)

If you are located in the European Economic Area, you have the right to access, correct, or delete your personal data at any time. You may also withdraw consent, request data portability, or object to processing. To exercise any of these rights, contact us at contact@oravelabs.com and we will respond within 30 days.

Third-party services

Our website is hosted on Framer. Our form is powered by Tally. Neither service sells your data. Both are GDPR-compliant. We do not use Google Analytics, Facebook Pixel, or any other tracking technology at this stage.

Contact

For any questions regarding this privacy policy or your personal data, please contact us at: contact@oravelabs.com — Oravé Labs, Monaco.

Biosensing · AI · Longevity

Intelligence
from within

Oravé Labs develops AI-driven biosensing technologies that transform biological signals into real-time health intelligence — non-invasive, continuous, and built for daily life.

Preventive HealthAI Biomarker IntelligenceNon-Invasive SensingMonaco · Nice · BucharestEarly Access — Late 2026Preventive HealthAI Biomarker IntelligenceNon-Invasive SensingMonaco · Nice · BucharestEarly Access — Late 2026

Redefining what it means
to know your body

The majority of preventable chronic conditions are preceded by measurable biological changes that go undetected for years. Current diagnostics are episodic, invasive, and reactive — designed to identify disease, not prevent it.

Oravé Labs is building the infrastructure for a different paradigm: continuous, non-invasive biosensing combined with AI-driven longitudinal analysis, designed to surface meaningful health signals before they become clinical events.

80%
of chronic diseases are preventable with early intervention
7y
average delay between first biomarker signal and clinical diagnosis
$6T
projected global cost of chronic disease by 2030
Biological signal · AI interpretation · Health intelligence
RAW SIGNALAI PROCESSEDINSIGHT
Continuous monitoringReal-time analysisLongitudinal patternsPredictive intelligenceNon-invasive

Advanced
biosensing,
reimagined

We are building next-generation sensing technologies designed to capture meaningful biological signals through seamless, everyday interactions — powered by machine learning that improves with every data point.

01
Biomarker Intelligence

Advanced biosensing approaches designed to capture meaningful biological signals — continuously, non-invasively, and without disrupting daily routine.

02
AI-Driven Insights

Complex biological signals transformed into clear health intelligence through machine learning models built on longitudinal personal data.

03
Seamless Integration

Health technology designed to fit naturally into existing daily behaviours — not another device to manage, but an invisible layer of biological awareness.

Phase 01
Stealth R&D
2024 – 2025
Core biosensing technology development. Signal processing architecture. AI model foundation.
Phase 02
Early Access
Late 2026
Closed cohort of selected participants. Platform validation. Iterative refinement with real-world data.
Phase 03
Beta Launch
2027
Expanded access. Clinical partnerships. Longitudinal study initiation. Integration ecosystem.
Phase 04
Full Launch
2028
Consumer and B2B market entry. Regulatory pathway completion. International expansion.
Dr. Alexandru Boamfă
Dr. Alexandru Boamfă
Founder & CEO
20 years as an oral surgeon with deep clinical expertise in biological diagnostics and human physiology. Leading Oravé Labs's vision, strategy and long-term direction.
LinkedIn ↗
Dr. Elena Magdalena Duculescu
Dr. Elena Magdalena Duculescu
Chief Medical Officer · Head of Clinical Research
20 years as a cardiologist with deep expertise in cardiovascular diagnostics and clinical research. Leading Oravé's medical direction and clinical validation programme.
LinkedIn ↗
Dr. Cristina Iancu
Dr. Cristina Iancu
Co-Founder · Clinical Affairs
10 years in general dentistry with extensive clinical experience in oral biology and patient diagnostics. Overseeing clinical affairs and operational validation of Oravé's platform.
LinkedIn ↗
Bogdan Boamfă
Bogdan Boamfă
Co-Founder · Platform Architect & IT Lead
Fractional CTO with extensive experience in platform architecture and engineering leadership. Directing all technology infrastructure at Oravé Labs.
LinkedIn ↗
Cristian Gamentz
Cristian Gamentz
Co-Founder · Business Development & Executive Management
20 years in business development, executive management and marketing. Driving Oravé's commercial strategy and strategic partnerships.
LinkedIn ↗
Engineering partners

Questions
answered

Yes. Oravé's biosensing approach is designed entirely around non-invasive signal capture — no needles, no blood draws, no disruption to your daily routine. Our methods are based on detecting biological signals through natural daily interactions.
The platform is designed to surface longitudinal biomarker trends and patterns rather than isolated readings — a continuous baseline of your biological state, with AI-generated insights that flag meaningful changes over time.
We are looking for health-conscious individuals, clinicians or researchers interested in the science, and institutional partners. Each group plays a different role in validating and shaping the platform before broader launch.
We are targeting a closed Early Access cohort for late 2026, with a broader beta in 2027. Signing up to the waitlist ensures you are considered for the first cohort.
Data privacy is foundational to our design. All biological data is encrypted, never sold, and you retain full ownership. Detailed privacy architecture will be published ahead of Early Access.
Early Access Program

Be first to
experience
the future

We are selecting a small group of early participants to shape the development of our platform. Share your interest and we will be in touch ahead of our 2026 launch.

No spam. We will only reach out when it matters.

How we handle
your data

Last updated: January 2025

Who we are

Oravé Labs is a health technology company incorporated in Monaco, with operations in Nice (France) and Bucharest (Romania). We are building an AI-driven biosensing platform for preventive health intelligence. This policy explains what personal data we collect, why we collect it, and how we handle it.

What data we collect

When you submit the Early Access waitlist form, we collect your name, email address, organisation (if provided), and your stated area of interest. We do not collect any biological, health, or medical data at this stage. We do not use cookies beyond those strictly necessary for the website to function.

Why we collect it

We collect your contact information solely to communicate with you about Oravé Labs — including updates on the platform, Early Access cohort selection, and relevant research developments. We will never send unsolicited commercial messages or share your data with third parties for marketing purposes.

How we store and protect it

Your form submissions are stored securely via Tally (tally.so), a GDPR-compliant form platform. Data is encrypted at rest and in transit. Access is restricted to Oravé Labs founders only. We retain your data only as long as necessary to fulfil the purpose for which it was collected.

Your rights (GDPR)

If you are located in the European Economic Area, you have the right to access, correct, or delete your personal data at any time. You may also withdraw consent, request data portability, or object to processing. To exercise any of these rights, contact us at contact@oravelabs.com and we will respond within 30 days.

Third-party services

Our website is hosted on Framer. Our form is powered by Tally. Neither service sells your data. Both are GDPR-compliant. We do not use Google Analytics, Facebook Pixel, or any other tracking technology at this stage.

Contact

For any questions regarding this privacy policy or your personal data, please contact us at: contact@oravelabs.com — Oravé Labs, Monaco.

Biosensing · AI · Longevity

Intelligence
from within

Oravé Labs develops AI-driven biosensing technologies that transform biological signals into real-time health intelligence — non-invasive, continuous, and built for daily life.

Preventive HealthAI Biomarker IntelligenceNon-Invasive SensingMonaco · Nice · BucharestEarly Access — Late 2026Preventive HealthAI Biomarker IntelligenceNon-Invasive SensingMonaco · Nice · BucharestEarly Access — Late 2026

Redefining what it means
to know your body

The majority of preventable chronic conditions are preceded by measurable biological changes that go undetected for years. Current diagnostics are episodic, invasive, and reactive — designed to identify disease, not prevent it.

Oravé Labs is building the infrastructure for a different paradigm: continuous, non-invasive biosensing combined with AI-driven longitudinal analysis, designed to surface meaningful health signals before they become clinical events.

80%
of chronic diseases are preventable with early intervention
7y
average delay between first biomarker signal and clinical diagnosis
$6T
projected global cost of chronic disease by 2030
Biological signal · AI interpretation · Health intelligence
RAW SIGNALAI PROCESSEDINSIGHT
Continuous monitoringReal-time analysisLongitudinal patternsPredictive intelligenceNon-invasive

Advanced
biosensing,
reimagined

We are building next-generation sensing technologies designed to capture meaningful biological signals through seamless, everyday interactions — powered by machine learning that improves with every data point.

01
Biomarker Intelligence

Advanced biosensing approaches designed to capture meaningful biological signals — continuously, non-invasively, and without disrupting daily routine.

02
AI-Driven Insights

Complex biological signals transformed into clear health intelligence through machine learning models built on longitudinal personal data.

03
Seamless Integration

Health technology designed to fit naturally into existing daily behaviours — not another device to manage, but an invisible layer of biological awareness.

Phase 01
Stealth R&D
2024 – 2025
Core biosensing technology development. Signal processing architecture. AI model foundation.
Phase 02
Early Access
Late 2026
Closed cohort of selected participants. Platform validation. Iterative refinement with real-world data.
Phase 03
Beta Launch
2027
Expanded access. Clinical partnerships. Longitudinal study initiation. Integration ecosystem.
Phase 04
Full Launch
2028
Consumer and B2B market entry. Regulatory pathway completion. International expansion.
Dr. Alexandru Boamfă
Dr. Alexandru Boamfă
Founder & CEO
20 years as an oral surgeon with deep clinical expertise in biological diagnostics and human physiology. Leading Oravé Labs's vision, strategy and long-term direction.
LinkedIn ↗
Dr. Elena Magdalena Duculescu
Dr. Elena Magdalena Duculescu
Chief Medical Officer · Head of Clinical Research
20 years as a cardiologist with deep expertise in cardiovascular diagnostics and clinical research. Leading Oravé's medical direction and clinical validation programme.
LinkedIn ↗
Dr. Cristina Iancu
Dr. Cristina Iancu
Co-Founder · Clinical Affairs
10 years in general dentistry with extensive clinical experience in oral biology and patient diagnostics. Overseeing clinical affairs and operational validation of Oravé's platform.
LinkedIn ↗
Bogdan Boamfă
Bogdan Boamfă
Co-Founder · Platform Architect & IT Lead
Fractional CTO with extensive experience in platform architecture and engineering leadership. Directing all technology infrastructure at Oravé Labs.
LinkedIn ↗
Cristian Gamentz
Cristian Gamentz
Co-Founder · Business Development & Executive Management
20 years in business development, executive management and marketing. Driving Oravé's commercial strategy and strategic partnerships.
LinkedIn ↗
Engineering partners

Questions
answered

Yes. Oravé's biosensing approach is designed entirely around non-invasive signal capture — no needles, no blood draws, no disruption to your daily routine. Our methods are based on detecting biological signals through natural daily interactions.
The platform is designed to surface longitudinal biomarker trends and patterns rather than isolated readings — a continuous baseline of your biological state, with AI-generated insights that flag meaningful changes over time.
We are looking for health-conscious individuals, clinicians or researchers interested in the science, and institutional partners. Each group plays a different role in validating and shaping the platform before broader launch.
We are targeting a closed Early Access cohort for late 2026, with a broader beta in 2027. Signing up to the waitlist ensures you are considered for the first cohort.
Data privacy is foundational to our design. All biological data is encrypted, never sold, and you retain full ownership. Detailed privacy architecture will be published ahead of Early Access.
Early Access Program

Be first to
experience
the future

We are selecting a small group of early participants to shape the development of our platform. Share your interest and we will be in touch ahead of our 2026 launch.

No spam. We will only reach out when it matters.

How we handle
your data

Last updated: January 2025

Who we are

Oravé Labs is a health technology company incorporated in Monaco, with operations in Nice (France) and Bucharest (Romania). We are building an AI-driven biosensing platform for preventive health intelligence. This policy explains what personal data we collect, why we collect it, and how we handle it.

What data we collect

When you submit the Early Access waitlist form, we collect your name, email address, organisation (if provided), and your stated area of interest. We do not collect any biological, health, or medical data at this stage. We do not use cookies beyond those strictly necessary for the website to function.

Why we collect it

We collect your contact information solely to communicate with you about Oravé Labs — including updates on the platform, Early Access cohort selection, and relevant research developments. We will never send unsolicited commercial messages or share your data with third parties for marketing purposes.

How we store and protect it

Your form submissions are stored securely via Tally (tally.so), a GDPR-compliant form platform. Data is encrypted at rest and in transit. Access is restricted to Oravé Labs founders only. We retain your data only as long as necessary to fulfil the purpose for which it was collected.

Your rights (GDPR)

If you are located in the European Economic Area, you have the right to access, correct, or delete your personal data at any time. You may also withdraw consent, request data portability, or object to processing. To exercise any of these rights, contact us at contact@oravelabs.com and we will respond within 30 days.

Third-party services

Our website is hosted on Framer. Our form is powered by Tally. Neither service sells your data. Both are GDPR-compliant. We do not use Google Analytics, Facebook Pixel, or any other tracking technology at this stage.

Contact

For any questions regarding this privacy policy or your personal data, please contact us at: contact@oravelabs.com — Oravé Labs, Monaco.